

Health professional feedback on HPV

vaccination roll-out in a developing country

ABSTRACT

Background: Worldwide, Zambia has the highest cervical cancer incidence rates (58.4/100,000 per year) and mortality rates (36.2/100,000 per year). The human papilloma virus (HPV) vaccine is considered a vital preventative measure against cervical cancer, particularly in sub-Saharan countries, such as Zambia. Past research suggests health professionals' experiences with HPV vaccination rollout can have practical implications for effective delivery.

Objective: To explore health professionals' perspectives on the HPV vaccination programme in Zambia.

Methods: Researcher travelled to Zambia and conducted semi-structured interviews with fifteen health professionals working in private, government, and missionary clinics/hospitals. Observation was conducted for triangulation purposes. Thematic analysis was used to analyse the data.

Findings: Five main themes emerged; medical misconceptions about the HPV vaccination, particularly with regards to infertility; fear of the unknown, including possible side effects and inadequate empirical research; need for prior desensitisation to resolve cultural barriers

prior to vaccination rollout; a rural-urban divide in health awareness, particularly in relation to cancer vaccines; and economic concerns associated with access to the HPV vaccination for most of the Zambian population.

Conclusion: Overall, the findings indicate that an essential avenue for facilitating HPV vaccination rollout in Zambia is by implementing a pre-rollout community effort that removes or softens cultural barriers, particularly in rural areas. It is also essential to correct erroneous HPV presumptions health professionals may have around infertility. Affordability remains a seemingly intractable hindrance that hampers HPV vaccination rollout in Zambia.

Key words; HPV; vaccination; Zambia; health professionals

INTRODUCTION

Cervical cancer is a major global health problem, rated as the third most common cancer in women [1]. Around 85% of cases occur in developing countries [2, 3]. Zambia in particular has the highest cervical cancer incidence rates (58.4/100,000 per year) and mortality rates (36.2/100,000 per year) worldwide [4]. Today, cervical cancer is the first cause of female cancer in Zambia, and the most common female cancer in women aged 15 to 44 years in this country [5]. Tackling cervical cancer in sub-Saharan countries is difficult, partly because multiple and complex socio-cultural factors contribute to its high mortality rates in these geographical regions [6].

HPV (human papilloma virus) infection is extremely detrimental for women in countries like Zambia, where the known adult HIV prevalence rate is 16% [7]. HIV and cervical cancer rates are strongly correlated [3]. HPV infection can double a woman's risk of acquiring HIV as it causes lesions in the cervix and vagina, which act as transmission sites

for the virus [8]. Not only are HIV positive women more likely to develop cervical cancer, but once contracted, cervical cancer develops even faster in HIV positive women [8]. Although systematic cervical cytology screening programmes are considered an essential tool for addressing cervical cancer in developing countries, research suggests these schemes aren't necessarily feasible in some developing countries [9]. One systematic review suggests lack of resources faced by less economically developed countries, like Zambia, limits women's access to both treatment and screening services, possibly contributing to the high prevalence of cervical cancer in such countries [3]. Knowledge of HPV is poor in many developing regions. For example, a study of 500 women in Sudan found that only 39.2% had heard about the HPV vaccination [10]. A similar investigation in Lebanon reported a knowledge score of just 52.7%, suggesting limited awareness of the vaccine [11]. However, knowledge of HPV appears to be relatively high in Zambia, with one study suggesting 74.7% of adult women have heard about cervical cancer, and 73.3% consider it preventable [12].

Pilot HPV vaccination programme in Zambia

The HPV vaccine was one of four new vaccines planned to be introduced into the routine immunization system in Zambia (the others comprising the rotavirus vaccine, pneumococcal, and the second dose of measles) [13]. However it has only been introduced on a pilot basis in three districts in the Lusaka province [14]. On 27 May 2013, the pilot scheme was launched, targeting schoolgirls (aged 9 to 13) in grade four. During the initial phase (2013 to 2014) approximately 50,000 girls were targeted [15]. Girls out of school were meant to receive the vaccine through outreach strategies and health centres [15]. Over the course of the pilot programme, from 2013 to 2014, an estimated 33,733 young girls were vaccinated with the full three doses [16]. The international organization Pink Ribbon Red Ribbon is donating an extra 30,000 vaccines [16]. As the HPV vaccine is one of the most expensive recommended

inoculations, its success is pivoted upon its affordability in limited resource settings [17]. The Global Alliance for Vaccines and Immunisation (GAVI) have taken steps to increase affordability and access to routine vaccines in low income countries [18]. Zambia was one of the countries approved for GAVI support, although at present the HPV vaccine does not appear to be one of the inoculations subsidised by the GAVI alliance [19].

Role of health professionals

It is estimated that about 500 health workers were trained (and 50 clinics involved) in the HPV vaccination programme in Zambia [20]. As Zambia has a doctor-patient ratio of just 0.173/1000 [21], and relatively few qualified gynaecologists – currently, there are only 40 members of the Zambia Association of Gynaecologists and Obstetricians [22] – how health professionals interact with their female patients, and their role in delivering the HPV vaccination, is an important issue to consider [23]. Health professionals can significantly amplify HPV vaccine uptake, for example by recommending vaccination during routine doctor-patient consultations [24]. It has also been argued that the potential success of the HPV vaccination can be improved if the challenges faced by healthcare providers are understood [25].

Some research has explored HPV-related knowledge and attitudes amongst health professionals from developing countries, including African countries [26-28]. For example, a questionnaire-based study of 602 Nigerian healthcare professionals concluded that while they had good knowledge of HPV, their awareness the vaccine was low [26]. Nurses in particular had the lowest level of knowledge about the HPV vaccine, or even its existence. Another quantitative study conducted in a South African hospital reported similar findings [27]. Using self-report questionnaires administered to 345 nurses, this study attempted to determine the factors that affect recommendations of HPV vaccination to patients. They found that the

majority of the nurses lacked understanding of HPV infections and vaccinations, but yet were still willing to recommend vaccinations to patients. These findings mirror those of another questionnaire based study of 178 female nurses in Nigeria [28]. The South African study also found that nurses who thought their patients would accept HPV vaccination were more likely to recommend it [27]. The authors concluded that before a HPV vaccination programme could be successful nationwide, nurses needed to receive more education on HPV in general, as well as the HPV vaccination specifically.

The present study

Overall, past research has shown that exploring health professionals' knowledge and views on HPV vaccination can yield valuable insights for vaccine implementation [27, 28]. Health workers' perceptions can influence their administration of the HPV vaccine. For example, interviews with 15 health professionals in exploring their views on cervical cancer screening concluded that professionals' perceptions of screening barriers influenced their management goals, practices and decisions surrounding how best to deal with cervical cancer [29]. Despite Zambia being particularly burdened by cervical cancer, and having recently benefited from a HPV vaccination pilot, no such study had been conducted in the region. The fact that Zambia has some of the highest cervical cancer mortality rates in the world emphasises the severity of the issue, and the requirement for health professional feedback on how to more effectively administer the HPV vaccination [4, 5, 30]. The views of health professionals involved in the HPV pilot scheme will be particularly helpful in identifying themes that may impede or facilitate vaccination rollout campaigns in this region. Thus, the current study aimed to address this gap in the literature, by exploring health professionals' experiences of the HPV vaccination rollout in Zambia.

METHODOLOGY

Thematic analysis was used as it allows the researcher to explore issues without the constraints that might otherwise be imposed by more structured analytical techniques, such as Interpretative Phenomenological Analysis (IPA) or GT [31]. A total of 15 healthcare professionals (4 males, 11 females) involved in cervical cancer were recruited from several health organisations in Kabwe, and also a private hospital/clinic, government hospital and district health center in Lusaka. Participants consisted of two gynaecologists, one oncologist, and twelve nurses. One professional worked in a private clinic, eight in a government hospital, one in a missionary hospital, one in a district health centre, two in an NGO hospice, and two at a cervical cancer clinic. The health worker (a nurse) from the district health centre was directly involved in running the pilot vaccination programme. Two professionals (nurses) working in Lusaka were parents/ guardians of girls targeted for vaccination. Given that there are only about 40 obstetrician/gynecologists in Zambia [22], finding anyone who knew about the HPV vaccine, or who worked on oncology wards, was a challenge. Health workers in charge of addressing cervical cancer found it hard to suggest who to talk to.

A Dictaphone was used to record the (semi-structured) interviews. The device was an Olympus VN- 711PC with 2GB memory (circa 823 hours of recordings), battery life of up to 72 hours, and USB connection for fast downloading to a PC. In order for the interviews to be standardized, each participant was asked the same ten core open-ended questions. These are presented in *Table 1*. Ethical approval was obtained from Liverpool John Moores University Research Ethics Committee (UREC), University of Zambia Biomedical Ethics Committee (UNZABREC, Ref. No. 004-06-15), and the Zambian Ministry of Health.

Figure 1 illustrates the key procedural steps. One of the researchers travelled to Zambia to recruit participants. Purposive sampling (specifically snowball sampling) was used. Recruitment was implemented through third-party recommendations (friends, family

and acquaintances). Although an hour was allocated for each interview, on average, an interview lasted about 30 minutes. Participants were informed both in the consent form and verbally that they had the right to withdraw from the study at any given time. With gatekeeper's approval, observation of some of the participants' places of work was also conducted. Observation consisted of the researcher taking field notes on the surrounding facilities and the interactions between staff and patients. Overall data collection took approximately 3 weeks.

Non-participant unstructured observation was conducted alongside the interviews to verify participants' reports. Following data analysis, some of the participants were contacted via email. They were presented with an outline of the findings, and asked to provide feedback. As the mother of one of the researchers had passed away with cancer, we were aware this might introduce some personal bias during data analysis. Thus, an inductive approach was used in data coding, to ensure it was primarily data-driven. However, it is important to note that the coding of data is never conducted in an 'epistemological vacuum'. Hence, the researchers acknowledged that the extent to which they were able to separate their subconscious thoughts from the analysis was limited [32].

.....

Insert Figure 1 here

.....

.....

Insert Figure 2 here

.....

.....

Insert Table 1 here

.....

174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198

.....

Insert Table 2 here

.....

RESULTS

Interview data was transcribed using the step-by-step procedure for thematic analysis outlined in the literature (see *Figure 2*) [31]. This process included generating initial codes (see *Table 2*), then searching for and reviving themes. A total of five overarching themes were derived from the data; ‘medical misconceptions’, ‘fear of the unknown’, ‘prior desensitisation’, ‘rural-urban divide’, and ‘economic concerns’.

Theme 1: Medical misconceptions

Despite the high-profile launch of the HPV vaccine roll-out in Zambia [15], participants expressed misconceptions and myths surrounding the vaccine which translated into a fear of the HPV vaccine in the community. Some of these misconceptions were that the vaccine causes infertility, illness such as cervical cancer itself, and that it is untested and Zambians are being used as experimental trials. Interestingly, one of the healthcare workers also held this belief:

"What I have heard about the vaccine, some say that it has been developed to reduce the population, to reduce the fertility in a woman, an African woman."

Participant J (L: 88-89)

"They were saying if they give those vaccines to young girls, maybe those young girls they won't get pregnant in the future, it will prevent them from getting pregnant, so those are beliefs that they have." Participant F (L: 16-18)

Theme 2: Fear of the unknown

It appears that health workers not directly facilitating the pilot programme were not given HPV vaccine training [20]. Thus suggesting that the informing of the healthcare workers on the vaccine was neither nationwide nor continuous. While most participants were in support of the vaccine, some had fears of the side effects and felt that not enough research had been done on it. This lack of knowledge even led to open rejection of the vaccine for one participant:

"I am telling you, about this vaccination, me I am against about it." Participant D
(L: 3)

In addition, although parents were meant to have been given information on the vaccine by the teachers or nurses that visited the schools [15], it was apparent that this was not always the case. For some of the nurses, this lack of information affected their preparedness to allow their child to be vaccinated or recommend it to the community.

"I feel they haven't done much work on it for them to even start giving a vaccine. And this is why I wasn't comfortable for my daughter to have the vaccine."

Participant I (L: 2-8)

"The females what they think about it, the others think that it is the wrong thing, they are scared, others they accept, but most of them they are scared. When the children tell their parents they want to give us this vaccine, most of the parents they

223 *were refusing saying ‘no us we don’t know about this drug’, so they refuse.”*

224 Participant M (L: 19-22)

225
226 Participants noted a lack of information on the HPV vaccine, contributing to the illusion not
227 much research has been done on it. This perceived knowledge deficit seemed to affect their
228 ability to deliver accurate vaccine information, and willingness to discuss the vaccine with
229 patients, and the community. It appears professionals in Kabwe were not given such
230 information as the pilot was carried out in the Lusaka district alone. However, even
231 participants from Lusaka reported that information had not been disseminated specifically to
232 them.

234 **Theme 3: Prior desensitisation**

235 Participants highlighted a need for specific cultural barriers to be addressed prior to rollout, to
236 make the whole community (including health professionals) more receptive to the vaccine.
237 This need for preliminary desensitisation was due to the cultural issues that were discussed,
238 such as females’ reliance on male or elder’s permission to vaccinate their children. During
239 the pilot children were sent home with consent slips, and parents were asked to sign them.
240 Obtaining consent may be problematic if significant males or elders are not educated on the
241 vaccine. Some participants felt that they have less influence over their patients than the males
242 or elders in the society.

243
244 *“The cultural background, that a woman should seek permission from her*
245 *husband, whether she should take her daughter for the vaccine. So those are*
246 *cultural issues that will always be there.”* Participant K (L: 155-158)

248 *“But with education we should include the male folk because mostly we side line*
249 *them, because they also play an important role, because if them the male folk*
250 *understand, it will be easy to encourage the wife or the mother to the child or the*
251 *daughter, it will be very easy.” Participant J (L: 122-125)*

253 **Theme 4: Rural-urban divide**

254 Participants perceived differences between the rural and urban communities in terms of
255 education levels. This lack of education in the rural communities in turn was perceived to
256 create challenges in delivering health education, and getting them to understand the need for
257 vaccinations.

258
259 *“When you speak to people with less education, or low education, they really*
260 *don’t understand why it is important. They even don’t understand what it means*
261 *to have cancer in the uterus and why the uterus is important. Or what it means to*
262 *have cancer. Because it is just lack of knowledge, lack of education.” Participant*
263 *G (L: 82-89)*

265 **Theme 5: Economic concerns**

266 The cost of the HPV vaccine was seen to be a barrier to vaccination for most of the Zambian
267 population. Participants stressed that if introduced in Zambia, the vaccine needs to be offered
268 for free, or at a reduced cost. It was also noted that the availability and promotion of the
269 vaccine would need to be sustained, especially as it is a multi-dosed vaccine. Issues regarding
270 access to the vaccine were also highlighted, especially by professionals located far away from
271 participating schools or health centres (e.g. cost of transport).

273 *“Because money is hard to come by in the current situation that there is, money*
274 *is very difficult to come by, and there are only a few in formal employment, a*
275 *large group they don’t have anything to do. So they can’t even be willing to spare*
276 *that pin (ZMK 1) on a vaccine, they would rather spend that on food.” Participant*
277 *L (L: 48-51)*

279 DISCUSSION

280 The main findings can be summarised as follows: (a) HPV vaccine education is needed for
281 health professionals; (b) concerns about unknown side effects and insufficient research may
282 dampen uptake; (c) resolving cultural hindrances prior to vaccine rollout is essential; (d)
283 increasing HPV education levels in rural communities is necessary, and (d) economic issues
284 need to be addressed. The implication that rural populations are especially vulnerable to low
285 HPV vaccination uptake (due to lack of education, and access to health care), and that the
286 cost of the vaccine is a major barrier, is consistent with past research [33].

287 Even with the support of organisations like GAVI’s support, access to the
288 vaccine remains a problem. However, economic barriers highlighted by participants were
289 focused primarily on the cost of service users accessing the vaccine, rather than its delivery.
290 Given that Zambia has a per capita income of about \$1,700, and 70% of the population live
291 below in poverty, many women may be unable to afford the cost of transportation to distant
292 participating schools or health centres [20]. Possible solutions include local training
293 programmes for doctors and nurses in remote areas, village-based screening, and use of
294 mobile hospitals [20].

295 Various studies have highlighted the need for improved HPV awareness in less
296 economically developed countries [10, 11, 34]. Medical knowledge may affect the support
297 provided by some health professionals [35, 36], but not others [27]. This seems to suggest the

relationship between knowledge of the vaccine and support for its rollout locally is complex. Health professionals attitudes are informed by factors beyond medical knowledge, such as past vaccination experiences [26]. Of particular interest here was the scepticism in the vaccine's safety and efficacy, despite the high profile launch of the vaccination programme [15]. Scepticism may discourage some health professionals from supporting its rollout [36]. Lack of information on the vaccine influenced beliefs in its safety, as well as willingness to recommend or discussed it with patients, correlating with past research [35]. Overall, the medical knowledge of some health professionals was a problem. Thus, it may be essential that health workers in this part of the world (including those not directly involved in administering the vaccine) are made aware that the HPV vaccine's safety has been approved by relevant international health authorities, and that there is published supporting evidence [37]. Even so, merely presenting existing research may not be sufficient 'proof' of the vaccine's safety for some. Apart from lack of vaccine literacy, there are some health professionals who will remain weary of the vaccine, due to the lack of longitudinal studies indicating its long-term effects [38]. Although this concern is understandable, as mentioned before, in countries so burdened by cervical cancer the rewards of a vaccine arguably outweigh the risks for the time being.

Other studies have highlight various cultural hindrances to vaccination rollouts in developing countries, based on health professional feedback [26-28]. However, the present emphasis on the authoritative control Zambian men have over women's health decision making (e.g. screening and vaccination) is unique to this study. This finding offers a unique insight into culture-specific barriers to the HPV vaccine in Zambia. Health professionals may be able to help address the issue, by using routine doctor-patient consultations, or local community outreach initiatives, to encouraging male patients to play a more constructive role in facilitating vaccination programmes. The misconception that the HPV vaccine causes

infertility is also a concern, seemingly associated with the gender-specific nature of HPV vaccination rollouts. Making the vaccine seem exclusive to women may fuel suspicions that it is being used as a form of population control by the government [39]. Thus, it may be helpful for health professionals to advise male patients to get vaccinated against HPV, as this has been shown to deflate such rumours [39]. Research suggests the general acceptability of the HPV vaccination in some African communities may be diminished by rumours, misunderstands, and fear about possible side effects (e.g., infertility), in addition to insufficient education about the vaccine [40]. To increase acceptance of the HPV vaccination in Zambia, health professionals need to find ways to educate local communities, not just about the importance of the HPV vaccination in cancer prevention, but also its role in the promotion of reproductive health (HPV infections are implicated in problematic reproductive functioning) [41].

Overall, despite the introduction of the HPV vaccination programme in Zambia, health professionals involved in the rollout harbour multiple concerns that may diminish their willingness to support the scheme. Perhaps, most worryingly, some professionals (nurses, more so than doctors) have misconceptions about the vaccine that may denote deficits in medical training, and/or deeper socio-cultural factors transcending professional knowledge. These findings have implications for other developing countries, where knowledge of the HPV virus is inadequate, such as Sudan [10], and Lebanon [11]. Efforts to improve knowledge levels will have limited effectiveness if the health professionals responsible for running the necessary educational schemes are themselves poorly informed about the virus, and/or harbour misconceptions that discourage them from supporting vaccination programmes.

Although research suggests widespread acceptance of HPV vaccine in Zambian women [12], the present findings nevertheless suggest a dire need for better understanding

amongst health workers of the role of the vaccine in advancing reproductive health. International organisations involved in vaccination rollout programmes (e.g., GAVI) should forge closer collaborative ties with Zambian (and other African) universities, to assist with developing new, or improving existing community educational programmes, to help correct rumours and misconceptions [18]. It is also necessary to identify and resolve cultural barriers around male authority, prior to offering the vaccination to female patients. While the present findings reflect experiences of health professionals, rather than the patients themselves, the key role played by the former in delivering vaccination services means their views can have a direct effect on patient outcomes [29]. Health professionals working in developing countries such as Zambia should recognise their own medical misapprehensions about HPV vaccination, and the reluctance of males and elders in local communities to support vaccination rollouts.

ACKNOWLEDGEMENTS

The authors would like to thank UNZABREC and the Zambian Ministry of Health for their co-operation. A special thanks also goes to Emma Harvey, Maggie Patel, the participants, and numerous gatekeepers, for their support.

CONFLICT OF INTEREST STATEMENT

There is no conflict of interest

REFERENCES

[1] Ladner J, Besson MH, Rodrigues M, Audureau E, Saba J. Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009-2013. BMC Public Health. 2014;14:670.

373 [2] White HL, Mulambia C, Sinkala M, Mwanahamuntu MH, Parham GP, Moneyham L, et
374 al. 'Worse than HIV' or 'not as serious as other diseases'? Conceptualization of cervical cancer
375 among newly screened women in Zambia. *Soc Sci Med.* 2012;74:1486-93.

376 [3] De Vuyst H, Alemany L, Lacey C, Chibwesha CJ, Sahasrabuddhe V, Banura C, et al. The
377 Burden of Human Papillomavirus Infections and Related Diseases in Sub-Saharan Africa.
378 *Vaccine.* 2013;31:F32-F46.

379 [4] Parham GP, Mwanahamuntu MH, Kapambwe S, Muwonge R, Bateman AC, Blevins M,
380 et al. Population-Level Scale-Up of Cervical Cancer Prevention Services in a Low-Resource
381 Setting: Development, Implementation, and Evaluation of the Cervical Cancer Prevention
382 Program in Zambia. *Plos One.* 2015;10.

383 [5] HPV Information Centre. Human Papillomavirus and Related Diseases Report -
384 ZAMBIA. Barcelona: Institut Català d'Oncologia; 2016.

385 [6] Zetola NM, Grover S, Modongo C, Chiyapo SP, Nsingo-Bvochora M, Narasimhamurthy
386 M, et al. Collision of three pandemics: The coexistence of cervical cancer, HIV infection, and
387 prior tuberculosis in the Sub-Saharan country of Botswana. *Journal of Global Oncology.*
388 2016;2:47-50.

389 [7] Kalima M, Lishimpi K, Meza JL, Watanabe-Galloway S, Msadabwe SC, Mwaba CK, et
390 al. Observed and Expected Incidence of Cervical Cancer in Lusaka and the Southern and
391 Western Provinces of Zambia, 2007 to 2012. *Int J Gynecol Cancer.* 2015;25:98-105.

392 [8] Ng'andwe C, Lowe JJ, Richards PJ, Hause L, Wood C, Angeletti PC. The distribution of
393 sexually-transmitted Human Papillomaviruses in HIV positive and negative patients in
394 Zambia, Africa. *Bmc Infect Dis.* 2007;7.

395 [9] Duraisamy K, Jaganathan KS, Bose JC. Methods of detecting cervical cancer. *Advance in*
396 *Biological Research.* 2011;5:226-32.

397 [10] Almobarak AO, Elbadawi AA, Elmadhoun WM, Elhoweris MH, Ahmed MH.
398 Knowledge, Attitudes and Practices of Sudanese Women Regarding the Pap Smear Test and
399 Cervical Cancer. *Asian Pac J Cancer Prev.* 2016;17:625-30.

400 [11] Dany M, Chidiac A, Nassar AH. Human papillomavirus vaccination: Assessing
401 knowledge, attitudes, and intentions of college female students in Lebanon, a developing
402 country. *Vaccine.* 2015;33:1001-7.

403 [12] Liu FW, Vwalika B, Hacker MR, Allen S, Awtrey CS. Cervical cancer and HPV
404 vaccination: Knowledge and attitudes of adult women in Lusaka, Zambia. *J Vaccines Vaccin.*
405 2012;3.

406 [13] DEFEATDD. Zambia national rotavirus vaccine rollout: New collaborative approaches
407 to accelerating vaccine introduction into resource-poor countries - the case of rota
408 introduction in Zambia. Seattle: PATH; 2013.

409 [14] Ntalasha H, Malungo JR, Merten S, Simona SJ. Influence of Food Supplements on
410 Testing for HIV and Aids and Adhering to Treatment in a Resource Poor Rural Setting: A
411 Case of Chivuna, Southern Zambia. *Science.* 2015;3:314-20.

412 [15] World Health Organisation. Human Papilloma Virus (HPV) vaccine introduced in
413 Zambia. Geneva, Switzerland: World Health Organisation; 2015.

414 [16] Asante E. Zambia – HPV Vaccines for All Washington, DC 20036 Pink Ribbon Red
415 Ribbon; 2016.

416 [17] Lazcano-Ponce E, Stanley M, Munoz N, Torres L, Cruz-Valdez A, Salmeron J, et al.
417 Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human
418 papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose
419 schedule at 21 months. *Vaccine.* 2014;32:725-32.

420 [18] Youngblood R. GAVI injects new life into HPV vaccine rollout. *Lancet.* 2013;381:1688.

421 [19] GAVI. GAVI alliance support. Geneva: GAVI; 2016.

- [20] Kapambwe S. Project to programme: Zambian experience. Paris: World Cancer Congress; 2016.
- [21] World Health Organisation. Density of physicians (total number per 1000 population, latest available year). Geneva: World Health Organisation; 2015.
- [22] Zambia Association of Gynaecologists & Obstetricians. ZAGO Fully paid up Members. Lusaka: Zambia Association of Gynaecologists & Obstetricians; 2015.
- [23] Cermak M, Cottrell R, Murnan J. Women's knowledge of HPV and their perceptions of physician educational efforts regarding HPV and cervical cancer. 2016-08-16T13:24:39Z2010-08138-003PIMain2010_05xmlFully PublishedYN20135209101007/s10900-010-9232-yEnglishengYY020Electronic0100Journal0110Peer Reviewed Journal36. 2010;35.
- [24] Hofstetter AM, Rosenthal SL. Factors impacting HPV vaccination: lessons for health care professionals. Expert Rev Vaccines. 2014;13:1013-26.
- [25] Bynum SA, Staras SAS, Malo TL, Giuliano AR, Shenkman E, Vadaparampil ST. Factors associated with Medicaid providers' recommendation of the HPV vaccine to low-income adolescent girls. 2016-08-16T13:24:39Z2013-34153-001PIMain2014_01xmlFully PublishedYN24064282101016/jjadohealth201308006EnglishengYY020Electronic0100Journal0110Peer Reviewed Journal3600Journal ArticleJOURarticleBynum, Shalanda ADepartm. 2014;54.
- [26] Audu BM, Bukar M, Ibrahim AI, Swende TZ. Awareness and perception of human papilloma virus vaccine among healthcare professionals in Nigeria. J Obstet Gynaecol. 2014;34:714-7.
- [27] Hoque ME, Monokoane S, Van Hal G. Knowledge of and attitude towards human papillomavirus infection and vaccines among nurses at a tertiary hospital in South Africa. J Obstet Gynaecol. 2014;34:182-6.

- [28] Makwe CC, Anorlu RI. Knowledge of and attitude toward human papillomavirus infection and vaccines among female nurses at a tertiary hospital in Nigeria. *Int J Womens Health*. 2011;3:313-7.
- [29] Mwaka AD, Wabinga HR, Mayanja-Kizza H. Mind the gaps: a qualitative study of perceptions of healthcare professionals on challenges and proposed remedies for cervical cancer help-seeking in post conflict northern Uganda. *BMC Fam Pract*. 2013;14:193.
- [30] Kapambwe S, Sahasrabuddhe VV, Blevins M, Mwanahamuntu MH, Mudenda V, Shepherd BE, et al. Implementation and Operational Research: Age Distribution and Determinants of Invasive Cervical Cancer in a "Screen-and-Treat" Program Integrated With HIV/AIDS Care in Zambia. *J Acquir Immune Defic Syndr*. 2015;70:e20-6.
- [31] Braun V, Clarke V. Using thematic analysis in psychology. 2016-08-16T13:24:39Z2006-06991-002PIMain2006_04xmlFully
PublishedYN101191/1478088706qp063oaEnglishengYY050Print0100Journal0110Peer
Reviewed Journal3600Journal ArticleJOURarticleBraun, Virginiavbraun@aucklandacnzDe.
2006;3.
- [32] Patton MQ. Two decades of developments in qualitative inquiry: A personal, experiential perspective. 2016-08-16T13:24:39Z2003-05113-001PIMain2002_08xmlFully
PublishedYN101177/1473325002001003636EnglishengYY050Print0100Journal0110Peer
Reviewed Journal3600Journal ArticleJOURarticlePatton, Michael QuinnMQPa. 2002;1.
- [33] Thomas TL, DiClemente R, Snell S. Overcoming the triad of rural health disparities: How local culture, lack of economic opportunity, and geographic location instigate health disparities. *Health Educ J*. 2014;73:285-94.
- [34] Hussain S, Nasare V, Kumari M, Sharma S, Khan MA, Das BC, et al. Perception of human papillomavirus infection, cervical cancer and HPV vaccination in North Indian population. *PLoS One*. 2014;9:e112861.

- [35] Hopkins TG, Wood N. Female human papillomavirus (HPV) vaccination: Global uptake and the impact of attitudes. *Vaccine*. 2013;31:1673-9.
- [36] Wamai RG, Ayissi CA, Oduwo GO, Perlman S, Welty E, Welty T, et al. Awareness, knowledge and beliefs about HPV, cervical cancer and HPV vaccines among nurses in Cameroon: An exploratory study. *Int J Nurs Stud*. 2013;50:1399-406.
- [37] Goncalves AK, Cobucci RN, Rodrigues HM, de Melo AG, Giraldo PC. Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review. *Braz J Infect Dis*. 2014;18:651-9.
- [38] Oscarsson MG, Dahlberg A, Tyden T. Midwives at youth clinics attitude to HPV vaccination and their role in cervical cancer prevention. *Sex Reprod Healthc*. 2011;2:137-42.
- [39] Leader AE, Weiner JL, Kelly BJ, Hornik RC, Cappella JN. Effects of information framing on human papillomavirus vaccination. *J Womens Health (Larchmt)*. 2009;18:225-33.
- [40] Turiho AK, Okello ES, Muhwezil WW, Harvey S, Byakika-Kibwikas P, Meya D, et al. Effect of School-based Human Papillomavirus (HPV) Vaccination on Adolescent Girls' Knowledge and Acceptability of the HPV Vaccine in Ibanda District in Uganda. *Afr J Reprod Health*. 2014;18:45-53.
- [41] Souho T, Benlemlih M, Bennani B. Human Papillomavirus Infection and Fertility Alteration: A Systematic Review. *Plos One*. 2015;10.